Drug Profile
Levorphanol - Relmada Therapeutics
Alternative Names: LevoCap; LevoCap ER; REL 1015; TQ-1020Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator TheraQuest Biosciences
- Developer Relmada Therapeutics
- Class Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; NMDA receptor antagonists; Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (PO, Controlled release)
- 09 Sep 2015 Relmada Therapeutics has patent protection for SECUREL technology and levorphanol in USA
- 12 May 2015 Relmada received a notice of allowance for the securel abuse deterrent technology in USA